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INTRODUCTION 
   In patients with symptomatic chronic heart failure (HF) the first line therapy consists of 
the pharmacological treatment with neurohormonal antagonists. Digitalis glycosides are 
also still in use. This medicine has been introduced into clinical practice more than 200 
years ago. Since that time, both drug and device therapy have evolved explosively and 
several observational studies raised concerns in terms of the safety of digitalis when used 
in patients on contemporary medications. On top of the aforementioned drug therapies 
implantable cardioverter defibrillators and cardiac resynchronisation therapy are the most 
important therapeutic modalities with reliable evidence for improving survival in HF. 
Since, not all HF patients benefit the same from these devices, the optimal patient 
selection is being studied extensively. Technical advances, for example combination with 
remote monitoring technics, provide further clinical directions and research goals in this 
field. This present work focuses on the safety of digitalis glycosides and novel functions 
and indications of cardiac resynchronisation therapy. 
 (A-B) The two main indications for the use of cardiac glycosides are the treatment of 
symptomatic heart failure (HF) in patients with impaired left-ventricular function and rate 
control in patients with atrial fibrillation (AF). The scientific evidence with respect to 
digoxin’s effects on heart failure is mainly based on two withdrawal studies [Uretsky et 
al. 1993; Packer et al. 1993] and one large randomised placebo-controlled trial [Garg et 
al. 1997]. With regards to the second indication, rate control in atrial fibrillation, there is 
not a randomised placebo-controlled study yielding supportive data. Nevertheless, both 
indications are endorsed by recent guideline recommendations [Ponikowski et al. 2016; 
Kirchhof et. al. 2016;]. However, it is well appreciated that digoxin has a narrow 
therapeutic window in part related to significant drug-drug interactions and may cause 
harm if not carefully administered including regular measurements of serum digoxin 
levels. A series of recent studies have cast serious doubt on the benefit of digoxin when 
added to contemporary HF treatment. In fact, some observations have indicated that 
digoxin may have a negative effect on mortality [Hallberg et al. 2007; Freeman et al. 
2013; Whitbeck et al. 2013; Turakhia et al. 2014; Shah at el. 2014; Gamst et al. 2014; 
Chao et al. 2014; Freeman et al. 2015; Pastori et al. 2015]. Moreover, there is a lack of 
data concerning the use of digitalis in implantable cardioverter defibrillator (ICD) 
patients. A recent subgroup analysis from MADIT-CRT showed an increased risk of 
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high-rate ventricular tachycardia/ventricular fibrillation episodes in patients treated with 
digitalis, but no difference in mortality [Lee et al. 2015].  
(C) Unfavourable prognostic impact of recurrent hospitalisations in HF is well known 
[Setoguchi et al. 2007]. Accordingly, several methods have been developed aiming at 
early detection of worsening HF with the potential for timely intervention to prevent 
hospitalisations and to improve survival. Some of the cardiovascular implantable 
electronic devices offer extended monitoring capabilities of vital parameters which may 
help to predict HF events. Yu et al. developed a detection algorithm called OptiVolTM to 
predict cardiac decompensation by applying Fluid Index derived from the changes of 
intrathoracic impedance, as a marker of lung fluid status [Yu et al. 2005]. However, the 
reliability of OptiVol remained contradictory in further clinical trials [Veldhuisen et al. 
2011; Conraads et al. 2011]. In the prospective multicentre PARTNERS HF study, the 
clinical utility of impedance monitoring could have been improved by using a combined 
device diagnostic algorithm based on additional parameters such as: new onset of atrial 
fibrillation, rapid ventricular rate during AF, low patient activity levels, high night heart 
rate, low heart rate variability, low percentage of biventricular pacing, and ventricular 
arrhythmias with ICD shocks [Whellan et al. 2010]. In this trial the strongest predictor 
was the elevated Fluid Index (i.e. OptiVol alert). Although the applied device diagnostic 
algorithm could predict the following hospitalisation with high probability, only 213 of 
1324 (16.1%) high-risk periods proved to be associated with true HF events. In further 
studies the number of false positive or unexplained OptiVol alerts also remained 
remarkably high despite the combination with remote monitoring techniques [Aizawa et 
al. 2014; Lüthje et al. 2015; Nishii et al. 2015].  
(D) The beneficial impact of newly implanted cardiac resynchronisation therapy on 
morbidity and mortality are well described in selected patients with heart failure [Al-
Majed et al. 2011; Cleland et al. 2013; Lewis et Gold 2015]. Patients already fitted with 
a conventional pacemaker or implantable cardioverter defibrillator (ICD) system are often 
considered for a CRT upgrade. In the latest European pacemaker and CRT guidelines, 
upgrade procedures from conventional pacemakers or ICDs to CRT are suggested as a 
class I indication (level B) for HF patients with a New York Heart Association (NYHA) 
functional class of III to ambulatory IV, left ventricular ejection fraction (LVEF) ≤35%, 
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and a high percentage of ventricular pacing [Brignole et al. 2013]. However, there is only 
weak scientific evidence about the outcomes of patients undergoing upgrade procedures. 
 
OBJECTIVES 
(A) In the light of such conflicting data, a systematic review of published data appears to 
be timely and may provide the best way to estimate the effectiveness and safety of digoxin 
therapy and to identify patient populations which are less likely to benefit. 
(B) We aimed to evaluate the effects of digitalis use in a large series of consecutive ICD 
recipients for the prevention of sudden cardiac death and who were followed for up to 10 
years in the University Hospital Frankfurt. 
(C) We hypothesized that the reliability of OptiVol alerts could be improved with some 
modifications of the original PARTNERS HF criteria considering more sensitive 
diagnostic values and the changes of pattern of these parameters. In our observational 
study, we aimed to compare the clinical applicability of the device diagnostic algorithm 
described in PARTNERS HF study to a newly developed algorithm applying refined 
diagnostic criteria. 
(D) We aimed to compare clinical response and long-term survival in a large cohort of 
consecutive patients receiving either de novo or upgrade CRT defibrillator (CRT-D) 
therapy. 
 
METHODS 
(A) Study selection. A comprehensive PubMed and Cochrane search was conducted 
from 1993 to November 2014 of the English literature dealing with the effects of digoxin 
on all-cause-mortality in patients with AF or congestive heart failure (CHF). Only full-
size articles of English language published in peer reviewed journals were considered for 
this meta-analysis. Randomised controlled trials, case-control studies, or cohort studies 
were eligible for this meta-analysis if the requirements, prospectively defined by our 
review protocol were met: (i) inclusion of AF or HF patient populations; (ii) report of 
adjusted results of effects of digoxin on all-cause-mortality; (iii) effect sizes provided as 
hazard ratios (HR). 
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Statistical analysis. All statistical analyses were conducted utilizing Comprehensive 
Meta-Analysis 3.3 (Biostat, Inc., USA). Heterogeneity between individual trial estimates 
was assessed using the Q statistic and I2 statistic. The principal measurement of effect 
size (i.e. all-cause mortality) was the HR along with the 95% upper and lower confidence 
intervals (CI). All selected non-randomised studies provided risk assessments which had 
been adjusted for important baseline clinical variables with different types of statistical 
methods (mostly Cox regression analysis or propensity-matched analysis). The random-
effect model was used to calculate HR for the overall effect and for the two subgroups 
(AF, CHF) in this meta-analysis. A forest plot was constructed showing the individual 
trials with the pooled estimates.  
 
(B) Patient population and outcomes. Our retrospective observational study is based on 
the analysis of data collected in consecutive patients who received an ICD or a cardiac 
resynchronisation defibrillator (CRT-D) at the J.W. Goethe University Frankfurt between 
1996 and 2010 and who were followed at the same institution. Follow-up data were 
prospectively collected from the index hospitalisation at the time of initial ICD 
implantation and at each follow-up visits that took place every 6 months or at the time of 
unscheduled visits in the out- or inpatient clinic. The primary outcome measure was time 
to all-cause mortality. Cause-specific mortality was defined according to the Hinkle and 
Thaler classification. 
Statistical analysis. Statistical analysis was performed using SPSS program version 22 
(IBM, USA). Baseline characteristics were compared by the Wilcoxon Mann-Whitney U 
test (continuous variables) and the χ2 test or Fisher exact test (categorical variables). 
Survival analysis was performed using Kaplan-Meier analysis. Survival curves were 
compared using the log-rank test and Wald test for the Cox proportional hazard model. 
Crude and adjusted hazard ratios (HR) with 95% CI for digitalis use were calculated for 
potential confounding factors including age, gender, primary/secondary prevention 
indication, ischaemic/non-ischaemic heart disease, NYHA classification, LVEF, ICD 
type, QRS width, documented AF, diabetes mellitus, and chronic renal disease. 
Independent predictors of mortality were derived by backward stepwise variable selection 
using Wald test in the multivariate Cox regression model.  
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(C) Study patients and study design. All consecutive patients implanted with an 
OptiVol and wireless telemetry capable CRT-D device (Medtronic Inc, Minneapolis, 
MN, US) in the Medical Centre of Hungarian Defence Forces and signed to be followed 
up via the CareLink remote monitoring system (Medtronic Inc, Minneapolis, MN, US) 
were prospectively recruited from April 2011 to June 2014. The optional function of 
intrathoracic impedance monitoring (OptiVol) was activated in all patients with an 
automatic remote alert, if the fluid index reaches 60 Ω-day. Patients were followed up at 
our outpatient HF clinic every 3 months or if clinically indicated. In-office device control 
was performed half-yearly by electrophysiologists. The transmitted CareLink data were 
evaluated by an electrophysiologist and HF specialist team weekly and within 24 hours 
for clinically relevant alerts. If an OptiVol alert occurred, patients were interviewed by 
an independent HF specialist for the presence of HF symptoms via telephone calls and 
during additional outpatient visits, as necessary. An OptiVol alert was categorized as true 
positive (verified HF event) when signs and symptoms of decompensated HF required an 
increase in diuretic dose in an outpatient setting or hospitalisation. 
Assessment of original PARTNERS HF criteria. The original PARTNERS HF criteria 
were evaluated for all OptiVol alerts (Fluid Index ≥ 60 Ω-day) using a time-frame window 
of 20 days prior to an alert, and sensitivity and specificity of the original PARTNERS HF 
device diagnostic algorithm were determined. 
New device diagnostic algorithm development. Our refined diagnostic algorithm was 
derived from an OptiVol alert (Fluid Index ≥ 60 Ω-day) and the presence of further 
positive parameters in a 20 days time-frame window prior to the alert. The following 
modified diagnostic criteria were utilized: 
• New AF episode: ≥ 6 h on at least 1 day  
• High ventricular rate during AF: average ventricular rate during AF ≥ 90 bpm 
on at least 24 h 
• Lower patient activity level for at least 5 days: 
o -2 h/day, if the prior average was ≥ 4 h/day  
o -1 h/day, if the prior average was < 4 h/day  
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o except (parameter was defined negative), if prior average was permanently 
under 1 h/day or activity decline was related to extra cardiac reason (e.g. 
elective surgery, musculoskeletal disorders, etc.) 
• Elevated nocturnal heart rate: average night HR > 85 bpm or elevated with ≥20 
bpm to the prior average for at least 5 consecutive days 
• Low heart rate variability: < 60 ms every day for 1 week, except (parameter 
was defined negative), if permanently under 60 ms 
• Low biventricular pacing rate: < 90% for at least 5 days, except (parameter was 
defined negative), if permanently <90% 
• Ventricular arrhythmias: treated by 1 or more ICD shocks or successful anti-
tachycardia pacing (ATP) 
Statistical analysis. Statistical analyses were performed using STATISTICA version 
10.0 (Tulsa, Oklahoma, USA), SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and 
MedCalc version 14.12.0 (Ostend, Belgium) softwares. Multivariate discriminant 
analysis was used to assess the association between device based parameters and 
progression of HF. Parameters independently associated with true HF events (p-value < 
0,05) were included in the final risk score. The predictive power of the original and 
refined clinical algorithms was described with sensitivity, specificity, positive and 
negative predictive statistics and the Receiver Operating Characteristic method (ROC-
analysis). To obtain an unbiased ROC analysis a cross-validation was performed. The 
cross-validation of ROC-curves and the confidence interval calculations were performed 
with the “Proc Logistic” procedure. 
 
(D) Patient population and outcomes. Implantation and outcome data were 
prospectively collected from consecutive patients undergoing CRT-D implantation at the 
J.W. Goethe University (Frankfurt, Germany), at the Evangelical Hospital Bielefeld 
(Bielefeld, Germany), and at the Medical Centre, Hungarian Defence Forces (Budapest, 
Hungary). CRT was considered for patients on optimized medical treatment with heart 
failure of NYHA functional class from II to IV, LVEF of ≤35%, and QRS width of >120 
ms (de novo group). Furthermore, patients with previously implanted pacemakers or 
ICDs, who developed the above-mentioned criteria with or without need for continuous 
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ventricular pacing were also considered for CRT (upgrade group). Patients were 
followed-up in the outpatient clinic of participating hospitals in 6 months’ intervals or 
when clinically indicated. Outcome measures were clinical response to CRT and long-
term mortality. Patients were considered to be responders if they survived to the 6 months 
follow-up visit with an improvement of at least 1 NYHA functional class. 
Echocardiographic data, including LVEF and left ventricular end-diastolic diameter 
(LVEDD), were also collected at baseline and reassessed at 6 months after the initiation 
of resynchronisation therapy. 
Statistical analysis. Statistical analysis was performed using SPSS Statistics software, 
version 23.0 (IBM, Armonk, NY) with the R software plug-in (The R Foundation, version 
3.1.0) for propensity score matching. The Kolmogorov-Smirnov test was used to evaluate 
the normal distribution of continuous data. The χ2 test was used to test for categorical 
variables and the 2-sample t test or the Mann-Whitney U test for continuous variables 
among patients groups. The effects of baseline parameters on response rate were assessed 
by the χ2 test and by a multivariate logistic regression model. To assess the effects of 
procedure type (i.e., de novo versus upgrade) on survival, the Cox proportional hazards 
regression model was used. The statistical models were adjusted for potential baseline 
confounders (listed in footnote of Table 2.). Univariate mortality risk assessment was also 
repeated among propensity score-matched patient groups. Patients receiving upgrade 
CRT were matched 1:1 with de novo subjects using the nearest neighbour matching 
method with a calliper of 0,2 by applying baseline characteristics as for the multivariate 
Cox regression. Survival curves were constructed according to the Kaplan-Meier method 
and compared with the Cox proportional hazard model and the Wald test for the 
multivariate analysis. In addition, survival analysis was repeated for subgroups according 
to NYHA functional class (NYHA II versus NYHA III–IV). 
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RESULTS 
 
(A) From a total of 1524 studies initially identified, 25 matched our search criteria. 
Additional six trials were excluded because they consisted of reports based on the same 
original trial database. This yielded a total of 19 studies which were selected for the 
present analysis. Nine reports dealt with AF patients, seven with patients suffering from 
CHF, and three with both clinical conditions. Patients were followed between 0,83 and 
4,7 years (average observation period 2,6±1,1 years) in the individual studies. Of all 
identified studies, only one was a randomized controlled clinical trial [Garg et al. 1997] 
whereas the remainder of studies were retrospective or prospective observational studies. 
   Based on the analysis of adjusted mortality results of all 19 studies comprising 326.426 
patients, digoxin use was associated with an increased relative risk of all-cause mortality 
(HR 1,21, 95% CI, 1,07 to 1,38, p<0,01)(Figure 1.). Compared with subjects not receiving 
glycosides, digoxin was associated with a 29% increased mortality risk (HR 1,29; 95% 
CI, 1,21 to 1,39) in the subgroup of publications comprising 235.047 AF patients. Among 
91.379 heart failure patients, digoxin-associated mortality risk increased by 14% (HR 
1,14, 95% CI, 1,06 to 1,22). 
   Six of the 19 studies reported data on the mean daily digoxin dose (0,126-0.250 mg) 
and/or the mean digoxin plasma levels (0,8-1,02 ng/ml). A sensitivity analysis of these 
studies revealed a similar HR (1,26, 95% CI, 0,91 to 1,74) as the analysis of all 19 studies, 
although this was no more statistically significant. 
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Figure 1. Forest plot of studies describing the effects of digoxin on mortality, both for studies in atrial 
fibrillation (AF) and congestive heart failure (CHF). Data had been adjusted for potential confounders in 
the various studies. 
 
(B) Patient population. A total of 1448 patients underwent ICD implantation at the 
University Hospital Frankfurt from 1996 to 2010 for primary or secondary prevention of 
sudden cardiac death. Of those, 1020 were regularly followed-up in the ICD outpatient 
clinic and formed the basis of this report. Of these, 561 (55%) received a single-chamber 
ICD, 295 (29%) a dual-chamber device, and 159 (16%) a CRT-D. The follow-up period 
ranged between 10 and 209 months (median 37 months). Digitalis medication was 
prescribed either for the treatment of CHF or for the control of ventricular rate in AF, or 
for both conditions. Patients treated with digitalis were older (median 63 years), were 
more often in AF (21 vs. 10%; p<0,001), and had worse left ventricular function (mean 
LVEF 26%) than patients not treated with digitalis (mean LVEF 38%; p<0,001). 
Intraventricular conduction disturbances with a QRS duration of ≥120 ms were present 
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in 47% of digitalis patients and in 33% of those without this medication. Patients on 
digitalis had significantly more co-morbidities such as diabetes mellitus and chronic 
kidney failure (p<0,001). 
All-cause mortality. During the observation period, 213 patients died, 128 treated with 
digitalis at baseline, and 85 not receiving this medication. Crude Kaplan-Meier survival 
analysis demonstrated a significantly higher mortality in patients who received digitalis 
at the time of ICD implantation compared with those not on this medication (HR 2,47; 
95% CI 1,87-3,25; p=0,001) (Figure 2.). To correct for potential confounders, Kaplan-
Meier analysis was repeated with data adjusted for all variables found significantly 
different between both patient groups in a multivariate analysis. These independent 
predictors of mortality were age, male gender, NYHA classification, and prolonged QRS 
duration. After adjustment, the risk for death continued to be higher among patients on 
digitalis compared with subjects not receiving digitalis (HR 1,65; 95% CI 1,14-2,39; 
p=0,01)(Figure 2.).  
 
 
Figure 2. Crude (A) and adjusted (B) Kaplan-Meier analysis of all-cause mortality by digitalis use. 
 
Cause-specific mortality. Among patients receiving digitalis, 37% suffered from cardiac 
arrhythmic, 24% from cardiac non-arrhythmic, and 11% from non-cardiac death. 
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Respective numbers for patients not on digitalis were 32% (p=0,044), 19% (p=0,036), 
and 12% (p= n.s.) Subsequently, more ICD shocks occurred in patients on digitalis 
compared with patients not on digitalis (HR = 1,30; 95% CI 0,93-1,80). For appropriate 
shocks HR was 1,74 (95% CI 1,14-2,65), and for inappropriate shocks a HR of 0,92 (95% 
CI 0,56-1,51) was found. 
Digoxin/digitoxin. Two different digitalis preparations were used in our patient 
population. The majority of the patients received digitoxin (n = 306), and digoxin was 
prescribed to 105 patients. The median prescribed daily dosages were in the 
recommended range (digitoxin: 0,035-0,10 mg/day; digoxin 0,05-0,20 mg/day). Plasma 
concentrations of digoxin (normal range at our institution: 0,8-2,0 mg/L) or digitoxin 
(normal range at our institution: 10,0-30,0 mg/L) at any time during follow-up could be 
retrieved by chart review in 220 patients (50%). In these patients, mean digoxin plasma 
concentration was 0,8 mg/L, and mean digitoxin plasma concentration was 21,6 mg/L. 
Concerning all-cause mortality, there was no difference between patients treated with 
digitoxin and patients treated with digoxin (HR 1,55; 95% CI 0,74-3,25; p=0,25). 
 
(C) OptiVol alerts and heart failure events. The average follow-up of the 42 enrolled 
patients was 38.0 ± 23.6 months. Five patients died, two underwent heart transplantation, 
one required an assist device implantation and in one case the CRT-D system had to be 
explanted due to infection. Altogether 722 remote transmissions were received during the 
follow-up period. After exclusion of eight transmissions due to the unavailability of HF 
specialist´s adjudication 128 of all transmissions with OptiVol alerts (Fluid Index ≥ 60 
Ω-day) were included in 
this analysis. Verified 
heart failure events were 
observed in 32 cases 
(25%)(Figure 3.) with 
need for hospitalisation 
in eight cases.  
 
 
Figure 3. Flowchart of CareLink transmissions during the study period. 
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Assessment of original PARTNERS HF criteria in our patient population. The 
classic PARTNERS HF diagnostic algorithm was positive in 31 of 32 cases with true 
deterioration of HF (sensitivity 96,9 %, CI 95% 83,8-99,9; negative predictive value 97,3 
%, CI 95% 85,8-99,9), however, the specificity remained very low with 60 false positive 
events (specificity 37,5 %, CI 95% 27,8-48,0%; positive predictive value 34,1 %, CI 95% 
24,5-44,7) (Table 1.). 
Table 1. Prognostic characteristics of the original and the refined diagnostic criteria. 
  
PARTNERS HF classic 
OptiVol + 1 modified 
criteria 
Sensitivity (95% CI) 96,9 % (83,8-99,9) 93,8 % (79,2-99,2) 
Specificity (95% CI) 37,5 % (27,8-48,0) 86,5 % (78,0-92,6) 
Positive predictive value (95% CI) 34,1 % (24,5-44,7) 69,8 % (53,9-82,8) 
Negative predictive value (95% CI) 97,3 % (85,8-99,9) 97,6 % (91,8-99,7) 
   
ROC-analysis / Area under the curve (95% CI)*  0,787 (0,704-0,869) 0,922 (0,869-0,974) 
Area under the curve with validation (95% CI)† 0,679 (0,568-0,790) 0,858 (0,767-0,948) 
*p between the two algorithms < 0,01; †p between the two algorithms < 0,01 
 
Assessment of the new device diagnostic algorithm. In the multivariate discriminant 
analysis of the refined diagnostic criteria lower activity levels, increased nocturnal heart 
rate, and suboptimal biventricular pacing proved to be independent predictors for cardiac 
decompensation (all p <0,001). Applying our refined algorithm which includes OptiVol 
alert events (Fluid Index ≥ 60 Ω-day) and the presence of at least one of the 
aforementioned modified diagnostic criteria, the number of false positive alerts decreased 
from 60 to 13 (specificity 86,5%, CI 95% 78,0-92,6%; positive predictive value 69,8%, 
CI 95% 53,9-82,8%) without compromising the sensitivity (sensitivity 93,8%, CI 95% 
79,2-99,2%; negative predictive value 97,6%, CI 95% 91,8-99,7%)(Table 1.). The 
diagnostic yield of the modified OptiVol algorithm assessed with ROC-analysis was also 
improved compared to classic PARTNERS HF diagnostic algorithm (AUC 0,787, CI 
95% 0,704-0,869 vs. AUC 0,922, CI 95% 0,869-0,974, p<0,01)(Table 1). On cross-
validation of the ROC-curves the difference between the two algorithms remained 
significant (AUC 0,679, CI 95% 0,568-0,790 vs. AUC 0,858, CI 95% 0,767-0,948, 
p<0,01)(Table 1).  
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(D) Patients Characteristics. A total of 552 CRT-D recipients (Frankfurt 332, Bielefeld 
103, and Budapest 117) were included in this analysis of whom 375 (68%) underwent a 
de novo implantation. A total of 177 patients (32%) had a previously implanted 
pacemaker or ICD system and underwent an upgrade procedure. Patients in the upgrade 
group were more often implanted for secondary prevention, suffered more often from 
atrial fibrillation, chronic kidney disease with a lower estimated glomerular filtration rate, 
diabetes mellitus, dyslipidaemia, and had more often a non-LBBB wide QRS complex, 
and a lower LVEF. Furthermore, amiodarone and digitalis were more often prescribed for 
patients undergoing upgrade procedures. 
Response to CRT. Follow-up data on the NYHA status at 6 months were available in 
96% of patients. After an upgrade procedure, 96 of 169 (57%) patients responded to CRT 
by improving their NYHA functional status by at least 1 class compared with 247 of 360 
(69%) patients in the de novo group (p=0,008). The lower response rate among upgrade 
patients remained statistically significant in a multivariate logistic regression analysis 
(p=0,021). The echocardiographic changes were in line with the results of observed 
response rates based on the assessment of NYHA functional class. The improvement of 
LVEF and the decrease of LVEDD at 6 months were higher in the de novo group 
compared to the upgrade 
patients (ΔEF 6,7±9,4 versus 
2,9±9,0, p<0,001; ΔLVEDD 
−3,5±6,7 versus 0,0±12,2, 
p=0,003; Figure 4.). 
 
 
 
 
Figure 4. LVEF at baseline and at 6 
months follow-up . 
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Mortality during follow-up. During a mean follow-up period of 37±28 months, survival 
was significantly worse among patients undergoing upgrade procedures compared to de 
novo CRT-D implantations (HR 1,65; 95% CI, 1,22-2,24; p=0,001)(Figure 5., Table 2.).  
After adjustment for potential confounders, all-cause mortality continued to be higher for 
patients in the upgrade group (adjusted HR 1,68; 95% CI, 1,20-2,34; p=0,002; Table 2.). 
Using a 1:1 nearest neighbour matching protocol, a cohort of 121 pairs of patients 
undergoing de novo or upgrade CRT operation was assembled. Compared with 
prematched patients, those in the matched 
cohort showed completely balanced clinical 
parameters across a spectrum of the 26 
baseline characteristics. Also in this 
propensity-matched cohort, patients 
undergoing upgrade procedures had a 
higher mortality risk than patients 
undergoing de novo implantations 
(propensity-adjusted HR 1,79; 95% CI, 
1,08-2,95; p=0,023; Table 2.). 
 
 
Table 2. Risk of death by implantation type: de novo versus upgrade CRT. 
 Univariate cohort 
(n=552) 
Multivariate cohort 
(n=501)* 
Propensity-matched 
cohort (n=242)† 
 HR (CI 95%) p-value HR (CI 95%) p-value HR (CI 95%) p-value 
All-cause 
mortality 
1,65 
(1,22-2,24)  
0,001 
1,68 
(1,20-2,34)  
0,002 
1,79 
(1,08-2,95) 
0,023 
 
*,† Models were adjusted for sex, age, primary prevention, aetiology, atrial fibrillation, hypertension, dyslipidaemia, 
diabetes, stroke/TIA, peripheral artery disease, chronic obstructive pulmonary disease, baseline NYHA class, baseline 
EF, LBBB, QRS with at baseline, eGFR, NYHA response, and therapy with antiplatelet drugs, anticoagulants, ß-
blockers, ACEIs/ARBs, diuretics, mineralocorticoid receptor antagonists, statins, amiodarone, and digitalis. 
Subgroup Analysis. Among patients with NYHA functional class II, there was no 
statistically significant difference in survival after de novo versus upgrade implantations 
(HR 1,27; 95% CI, 0,61-2,65; p=0,527). However, in the subgroup of patients with 
NYHA class III–IV, the risk of all-cause mortality was higher in the upgrade group (HR 
1,67; 95% CI, 1,19-2,35; p=0,003). 
Figure 5. Kaplan-Meier curves for all-cause mortality 
by implantation type. 
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CONCLUSIONS 
(A) Our meta-analysis on the effects of digoxin on all-cause mortality is the largest one 
published until April 2015. It is based on 19 published studies comprising data from more 
than 300 000 patients suffering from AF or CHF. Our results indicate that digoxin therapy 
is associated with an increased mortality risk in these patients, particularly in those treated 
for AF. Coupled with the notion emphasized by Rathore et al. [Rathore et al. 2003], this 
calls for randomised trials of dose-adjusted digoxin therapy. Until such proper 
randomised controlled trials are being completed, digoxin should be used with great 
caution, including monitoring plasma levels. 
(B) In our retrospective, single-centre, long-term study of consecutive ICD recipients, we 
first described that digitalis use was independently associated with an increased mortality 
risk in this particular patient population. In addition, there was no difference in the 
mortality risk between patients treated with digitoxin or with digoxin. Digitalis therefore 
should be used with great caution in clinical practice. Randomised placebo-controlled 
trials of digitalis use in patients with heart failure are urgently warranted. 
(C) Our refined device diagnostic algorhythm based on the parameters of low activity 
level, high nocturnal heart rate, and suboptimal biventricular pacing could improve the 
clinical reliability of OptiVol alerts. Our results are hypothesis generating, and hence this 
strategy of risk assessment should be prospectively tested in larger patient cohorts. 
(D) Both clinical response and long-term outcome were less favourable in patients 
undergoing CRT-D upgrade compared to de novo implantation in our multicentre, 
observational study, even after careful adjustment for possible confounders. These 
findings warrant confirmation in prospective randomised trials, such as the ongoing 
BUDAPEST-CRT Upgrade Study [NCT02270840]. Until these results become available, 
our observations need to be considered when counselling individual patients on the need 
for a CRT upgrade. 
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